Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sorrento Therapeutics Inc | SRNE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3073 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.161 - 3.09 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.3073 | USD |
Sorrento Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 168.36M | 547.88M | 543.18M | $ 52.90M | $ - | -1.43 | -0.20 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 495.00 | 19.90% |
Sorrento Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRNE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 1.13 | 1.23 | 0.161 | 0.4141098 | 52,397,082 | -0.8227 | -72.81% |
6 Months | 1.61 | 1.89 | 0.161 | 0.622909 | 23,309,970 | -1.30 | -80.91% |
1 Year | 2.46 | 3.09 | 0.161 | 1.09 | 15,799,021 | -2.15 | -87.51% |
3 Years | 1.87 | 21.26 | 0.161 | 6.19 | 16,300,506 | -1.56 | -83.57% |
5 Years | 7.20 | 21.26 | 0.161 | 5.93 | 10,788,693 | -6.89 | -95.73% |
Sorrento Therapeutics Description
Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for the treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody-drug conjugates. |